SmartPill Capsule Clinical Trials are Underway at the University of Kansas Medical Center
The SmartPill Corporation, developer of the SmartPill Capsule, an ingestible medical device that captures biomedical data from within a patient’s GI tract, today announced that significant progress is being achieved in on-going clinical trials of its SmartPill ACT-I Capsule and GI Monitoring System, and that clinical testing of its innovative product has begun at the University of Kansas Medical Center in Kansas City, Kansas.
Buffalo, NY (PRWEB) July 21, 2005 -– The SmartPill Corporation (www.smartpillcorp.com),
developer of the SmartPill Capsule, an ingestible medical device that captures
biomedical data from within a patient’s GI tract, today announced that
significant progress is being achieved in on-going clinical trials of its
SmartPill ACT-I Capsule and GI Monitoring System, and that clinical testing of
its innovative product has begun at the University of Kansas Medical Center in
Kansas City, Kansas.
A total of 20 subjects, 10 Normals and 10
Gastroparetics, are expected to participate in the University of Kansas clinical
research study. Richard W. McCallum, M.D., Professor of Medicine, and Director
of the Center for Gastrointestinal Nerve and Muscle Function at the University
of Kansas Medical Center (KUMC), University of Kansas, is the principal
investigator. As with the other fives sites participating in SmartPill clinical
trials, the primary objective of the KUMC study is to demonstrate the
correlation of gastric residence times measured by the SmartPill ACT-I Capsule
and conventional gastric emptying scintigraphy.
David Barthel, president
and CEO of The SmartPill Corporation, said, “The progress we and our partners
are achieving is most impressive. Five internationally recognized GI motility
centers are participating in the trial, soon to be seven, and we are well on our
way toward achieving our objective of testing more than 130 subjects. To date,
nearly 60 subjects have participated in the trial and the preliminary
indications are extremely encouraging. I am also very pleased that the
University of Kansas Medical Center and noted Gastroenterologist and researcher
Dr. Richard McCallum have agreed to support our efforts. Dr. McCallum is a
leader in the GI motility field, and he and his team are expected to drive
testing of Gastroparetics.”
The University of Kansas Medical Center study
is expected to run 6 - 8 weeks, paralleling clinical trials underway at
Massachusetts General Hospital (Boston, MA), Temple University Hospital
(Philadelphia, PA), Wake Forest (Winston-Salem, NC), University at Buffalo
(Buffalo, NY), and the University of Louisville (Louisville, KY).
About
the University of Kansas Medical Center
The University of Kansas Medical
Center (KUMC) is a major public research and teaching institution that operates
through a diverse, multicampus system. KUMC's many parts are bound together by a
mission to serve as a “center for learning, research, scholarship and creative
endeavor” in the state of Kansas, the nation and the world. For more
information, see www.kumc.edu.
About The SmartPill Corporation
The
SmartPill Corporation is the developer of the SmartPill ACT-I Capsule and
SmartPill GI Monitoring System that will non-invasively aid in the definition,
diagnosis, and therapeutic intervention of GI motility disorders; present a more
comfortable and convenient alternative to invasive GI diagnostic procedures; and
reduce the cost of exploratory GI examinations. Learn more at www.smartpillcorp.com or
call The SmartPill Corporation at 800.644.4162.
# # #
Source : http://www.prweb.com/releases/2005/7/prweb264136.htm